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Abstract
Hypoglycemia is the acute complication of diabetes mellitus and the commonest 
diabetic emergency and is associated with considerable morbidity and mortality. 
It can be caused by too much insulin intake or oral hypoglycemic agents, too little 
food, or excessive physical activity. The level of glucose that produces symptoms of 
hypoglycemia varies from person to person and varies for the same person under 
different circumstances. It characterized by sweating, tremor, tachycardia, palpita-
tion, nervousness, hunger, confusion, slurred speech, emotional changes, double 
vision, drowsiness, sleeplessness, and often self-diagnosed which may leads to 
serious symptoms of seizure, cognitive impairment, coma and death. The immedi-
ate treatment of hypoglycemia should be known by all the diabetic patients, so 
that need for hospitalization could be avoided. Hypoglycemia and its severity can 
be prevented by early recognition of hypoglycemia risk factors, self-monitoring 
of blood glucose, selection of appropriate treatment regimens, appropriate educa-
tional programs for healthcare professionals. The major challenges of the treatment 
of hypoglycemia are good glycemic control, minimize the risk of hypoglycemia and 
thereby minimize long-term complications. Hence there is an urgent need to under-
stand the clinical spectrum and burden of hypoglycemia so that adequate control 
measures can be implemented against this life-threatening complication.
Keywords: blood glucose, diabetes mellitus, glucagon, glycemic index, 
hypoglycemia, insulin
1. Introduction
The blood sugar level, blood sugar concentration, or blood glucose level is the 
amount of blood sugar level in the blood. Glucose is required for cellular respira-
tion and is the preferred fuel for all body cells. Plasma glucose concentration is the 
balance between the rate of glucose entering the circulation and the rate of removal 
of glucose from the circulation. Circulating glucose comes from intestinal absorp-
tion from the ingestion of carbohydrate during the fed state and by the process of 
glycogenolysis, and gluconeogenesis in the fasting state. Glycogenolysis is the bio-
chemical breakdown of glycogen into glucose which takes place in the cells of the 
muscle and liver in response to hormonal and neural signals. Gluconeogenesis is 
the metabolic process of generation of glucose from non-carbohydrate substances 
such as protein and fat which takes place in the liver and kidney in response to dia-
betogenic hormones. There are hormones involved in glucose regulation are called 
glucoregulatory hormones which include insulin, glucagon, amylin, glucogan-like 
peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), epinephrine, 
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cortisol, and growth hormone. Among, insulin and amylin are secreted from the 
β-cells of islets of Langerhans, glucagon from the α-cells of islets of Langerhans of 
the pancreas, GLP-1 from the small intestine and colon, and GIP from upper small 
intestine. If these glucoregulatory or counter-regulatory hormones fail to balance 
the blood sugar level causes hypoglycemia or hyperglycemia.
Hypoglycemia, also called low blood glucose or low blood sugar, occurs when 
the level of glucose in blood drops below normal. The term literally means “under-
sweet blood”. It may also be referred to as an insulin reaction, or insulin shock. This 
condition typically arises from abnormalities in the mechanisms involved in glucose 
homeostasis. Hypoglycemia is the commonest diabetic emergency and is associated 
with considerable morbidity and mortality. The American Diabetes Association 
defines the hypoglycemia as any abnormally low plasma glucose concentration 
that exposes the subject to potential harm [1]. Hypoglycemia is common in insulin 
dependent diabetic patients and may also occur in patients with non-insulin-
dependent diabetes mellitus. It can be caused by too much insulin intake or oral 
hypoglycemic agents or too little food or excessive physical activity [2]. The other 
causes or risk factors of hypoglycemia are dosage, combination of anti-diabetic 
drugs, timing of consuming the drug and anti-diabetic drug with simultaneous use 
of other interacting drugs. The symptoms of hypoglycemia depend on the level of 
blood glucose and vary from one person to another person and also vary within the 
same person under different circumstances [3]. It may range from a very mild with 
minimal or no symptoms (60–70 mg/dl), to severe hypoglycemia, and neurological 
impairment (<40 mg/dl) [4].
2. Prevalence of hypoglycemia in diabetes
Hypoglycemia is one of the most feared complications of diabetes treatment [5]. 
Individuals who take insulin, which includes all people with T1DM and some people 
with type 2 diabetes, are prone to hypoglycemia [6]. Hypoglycemia commonly 
occurs in clinical practice as approximately 90% of all patients who receive insulin 
have experienced hypoglycemic episodes [7]. Furthermore, surveys investigating 
the prevalence of hypoglycemia have provided some alarming results. The Diabetes 
Control and Complication Trial (DCCT) reported a threefold increase in severe 
hypoglycemia and coma in intensively treated T1DM patients versus convention-
ally treated patients [8]. A meta-analysis study reported that the prevalence of 
hypoglycemia was 45% for mild/moderate and 6% for severe. Incidence of hypogly-
cemic episodes per person-year for mild/moderate and for severe was 19 and 0.80, 
respectively. Hypoglycemia was prevalent among patients on insulin; among, the 
prevalence of mild-moderate and severe hypoglycemia episodes was 50 and 21%, 
respectively. Similarly, among patients on the treatment of sulfonylurea, the preva-
lence of mild-moderate and severe hypoglycemia was 30 and 5%. It was also found 
5% of prevalence among those who did not include sulfonylureas in the treatment 
regime [9].
A population-based study conducted in the UK to determine the frequency 
and predictors of hypoglycemia in type one diabetic patients. The study findings 
concluded that type 1 diabetes mellitus patients who are on intensive treatment 
may experience up to 10 episodes of symptomatic hypoglycemia per week and 
severe temporarily disabling hypoglycemia at least once a year [10]. It is estimated 
that 2–4% of deaths occur in people with type 1 diabetes due to hypoglycemia [11]. 
Hypoglycemia is also equally common in type 2 diabetes, with prevalence rates of 
70–80% [12]. Donnelly et al. who conducted a survey with 267 individuals with 
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type 1 diabetes and insulin-treated type 2 diabetes to record hypoglycemic events 
over a 4-week period and 155 individuals reported 572 incidents of hypoglycemia. 
Of these, the rate of hypoglycemia events in type 1 diabetic was 43 per patient per 
year whereas in type 2 diabetes was 16 events per patient per year. The predictor of 
hypoglycemia for individuals with type 1 diabetes and insulin-treated type 2 diabe-
tes was a history of previous hypoglycemia and duration of insulin treatment [10]. 
Similarly other study findings also concluded that hypoglycemia occurs more often 
than previously reported [12] in insulin-treated type 2 diabetes and with sufficient 
frequency to cause significant morbidity.
3. Risk factors for hypoglycemia
Several factors influence an individual at risk (Table 1) for a hypoglycemic 
episode. These include a mismatch in the timing, amount, or type of insulin, 
skipping meals, eating small meal, irregular dietary pattern and lack of physical 
activity. Additional factors such as alcohol consumption, obesity, elderly people, 
liver disorders, renal disease, adrenal insufficiency (glucocorticoid or catechol-
amine deficiencies) and pituitary insufficiency and leukemia which increase the 
risk for hypoglycemia. Other factors at risk are those who have ingested medi-
cation salicylates and those who have surgery with general anesthesia, which 
places them in an altered state of consciousness and hyper-metabolic state [13].
Another potential risk for hypoglycemia is the use of β-blocker and ACE inhibi-
tor medication in cardiac and hypertensive patients which mask the symptoms of 
hypoglycemia. β-Blockers inhibit the secretion of insulin and glycogenolysis due 
to diminishing of adrenergic counter regulation and also conceal the symptoms 
of catecholamine-mediated neurogenic hypoglycemia such as tremor, palpitation, 
hunger, irritability and confusion. However sweating remains unmasked and may 
be the only sign of patients treated with β-blockers [14].
Medical-related factors
• Strict glycemic control
• Previous history of severe hypoglycemia
• Long duration of type 1 diabetes
• Duration of insulin therapy in type 2 diabetes
• Lipohypertrophy at injection sites
• Impaired awareness of hypoglycemia
• Severe hepatic dysfunction
• Impaired renal function (including those patients requir-
ing renal replacement therapy)
• Sepsis
• Inadequate treatment of previous hypoglycemia
• Terminal illness
• Cognitive dysfunction/dementia
Lifestyle-related factors
• Increased exercise (relative to usual)
• Irregular lifestyle
• Alcohol
• Increasing age
• Early pregnancy
• Breast feeding
• No or inadequate blood glucose 
monitoring
Reduced carbohydrate intake/absorption
• Food malabsorption, e.g., gastroenteritis, 
coeliac disease
• Bariatric surgery involving bowel 
resection
Other factors:
• Hypoglycemia unawareness
• Number of years since diabetes diagnosis
• Time since insulin initiated
Table 1. 
Risk factors of hypoglycemia.
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4. Causes of hypoglycemia
Hypoglycemia is commonly occur in people with both type 1 and type 2 diabetes 
taking insulin or certain oral hypoglycemic agents. The common causes of hypogly-
cemia are:
4.1 Insulin and oral hypoglycemic agents
Diabetes medications such as insulin and Sulfonylureas are the most common 
causes of hypoglycemia in diabetic subjects [15]. Of these, Insulin is a definite 
cause of low blood glucose. One reason why newer insulin are preferred over 
NPH and regular insulin is that they are less likely to cause blood glucose lows, 
particularly overnight. Insulin pumps may also reduce the risk for low blood 
glucose. Accidentally injecting the wrong insulin type, too much insulin, or 
injecting directly into the muscle instead of subcutaneous can cause low blood 
glucose. The long-acting sulfonylureas such as glibenclamide and chlorprop-
amide are associated with more severe hypoglycemia than the shorter-acting 
drugs [16]. Metformin was the most frequent used oral hypoglycemic agents 
(66.4%) followed by sulfonylurea and the most prevalent combination therapy 
was metformin/glibenclamide regimen (28.5%). The majority of patients treated 
with metformin at the time when they were diagnosed with diabetes (45.3%). 
Hypoglycemic episodes were most commonly reported adverse events with 
insulin and gastric upset with oral hypoglycemic agents. 60.3% of the patients did 
not follow regular blood glucose checkup [17]. Several reports reveal that various 
pharmacological agents like metformin, rosiglitazone, etc., which have wide rang-
ing side effects, including weight gain, hypoglycemia and risk of coronary heart 
disease [18]. Occasionally episodes of hypoglycemia may occur with metformin, 
as the most commonly used anti-diabetic drug, due to an imbalance between food 
intake and dose of metformin [19].
4.2 Food pattern
Eating foods with less carbohydrate than usual without reducing the amount of 
insulin taken. Timing of insulin based on whether consumption of carbohydrates 
is from liquids or solids which can affect blood glucose levels. Liquids are absorbed 
much faster than solids, so timing the insulin dose to the absorption of glucose from 
foods. The composition of the meal contains the amount of fat, protein, and fiber 
which can also affect the absorption of carbohydrates.
4.3 Dietary habit
If meal is skip or delay, blood glucose could drop too low. Hypoglycemia also can 
occur when asleep and have not eaten for several hours.
4.4 Drinking alcohol
Alcohol consumption increase the insulin secretion and makes the liver not to 
release the glucose effectively into the blood circulation especially if have not eaten 
enough food within around 6 h and also makes more difficulty to generate new glu-
cose by liver. Hypoglycemia occur overnight if fall asleep after consuming alcohol 
without eating food among people with diabetes.
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4.5 Physical activity
Exercise has plays a vital role and has many potential health benefits. However 
the exercise can lower blood glucose by utilizing glucose for energy. Nearly half 
of the individual with diabetes mellitus who exercised an hour during the day 
may experience a low blood glucose reaction overnight. The factors influencing 
exercise induce hypoglycemia are the intensity, timing of exercise and dura-
tion. Hypoglycemia can occur during, 1–2 h after, or up to 17 h after exercise. 
Endogenous insulin secretion is reduced up to 40–60% while doing moderate-
intensity exercise among non-diabetic individuals. Hence it is mandate that 
decrease insulin dose or increase glucose intake is recommended before, during or 
after exercise depending on the intensity of exercise to prevent exercise associated 
hypoglycemia.
Additionally, recent studies have observed the cruel cycle of counter-regulatory 
failure between exercise and hypoglycemia. Thus, subsequent two episodes of pro-
longed, moderate-intensity exercise can inhibit autonomic nervous system and neu-
roendocrine responses by 50%. Similarly, 40–50% of counter-regulatory responses 
reduced during two episodes of antecedent hypoglycemia due to subsequent exercise 
[20]. Hence, there is a greater risk of hypoglycemia during exercise among individu-
als who have had a previous episode of hypoglycemia. This may be prevented by 
adjusting pre-exercise insulin dose, and consuming appropriate amounts of glucose.
4.6 Potential causes of in-patient hypoglycemia
Common causes of inpatient hypoglycemia are listed in Table 2. One of the most 
serious and common causes of inpatient hypoglycemia are insulin prescription 
errors including:
• Misreading poorly written prescriptions
• Confusing the insulin name with the dose
Treatment-related causes Glucose intake-related causes
• Inappropriate use of short acting insulin
• Incorrect prescription and administration insulin or oral 
hypoglycemic agent
• Mismatch between insulin/oral hypoglycemic therapy 
and meal or enteral feed
• Acute withdrawal of long term steroid therapy
• Recovery from stress of critical illness
• Polypharmacy
• Mobilization after illness
• Amputation of limb
• Intravenous insulin infusion with or without glucose 
infusion
• Failure to monitor blood glucose adequately especially on 
Intravenous insulin infusion
• Reduced carbohydrate intake than 
normal
• Anorexia
• Nausea and/or vomiting
• Nothing by mouth orders
• Delay in serving food tray
• Poor coordination in meal and medica-
tion timing
• Skipping of meal
Table 2. 
Etiological factors of hypoglycemia.
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• Confusing the insulin strength with the dose
• Transcription errors
• Inappropriately withdrawing insulin using a standard insulin syringe
• Confusion between the prescription of a glucose and insulin infusion for 
hyperkalemia and glucose and
• insulin infusion to blood glucose control
5. Physiology of glucose counter-regulation
The most metabolically active organ is brain and it is the first organ affected by 
lower blood glucose level. The brain requires continuous supply of oxygen and glu-
cose to meet the needs of energy requirement as it does not store excess energy and 
derives almost all of its energy from aerobic oxidation of glucose. Hence brain cells 
are vulnerable to glucose deprivation and also cannot survive more than 5–6 min 
without glucose. The sequence of counter-regulatory response will play significant 
role when the blood glucose levels fall below 70 mg/dl to protect the brain from 
further deterioration of effects of hypoglycemia.
Decline in Blood glucose levels below the physiological range may trigger hierar-
chically organized sequence of responses in the non-diabetic individual [21, 22]. It 
includes release of neuroendocrine hormones or counter-regulatory or anti-insulin 
hormones, stimulation of the autonomic nervous system (ANS), and manifestation 
of neurogenic and neuroglycopenic symptoms. Pancreatic beta cells suppressed the 
insulin secretion when blood glucose levels declines within the physiological range 
results in reduction of peripheral glucose uptake and increase in hepatic glucose 
production to prevent true hypoglycemia. In further, declining intra-islet insulin 
plays an important role for the glucagon response to hypoglycemia by increase the 
release of glucagon by pancreatic alpha cells [23–25] and pancreatic polypeptide 
from the pancreas. Similarly catecholamines such as epinephrine secreted from 
the adrenal medullae and norepinephrine from sympathetic postganglionic nerve 
terminals and adrenal medulla. Cortisol from the adrenal cortex and growth 
hormone from the anterior pituitary gland also triggered when blood glucose level 
falls. The primary physiological fast acting hormones in response to hypoglycemia 
are glucagon and epinephrine.
Glucagon hormones enhance endogenous glucose production by the process 
of glycogenolysis and gluconeogenesis and generating glucose substrates such as 
lactate, pyruvate, alanine, and glycerol. In addition, epinephrine also has similar 
effects like glucagon in increase of endogenous glucose production and inhibition 
of utilization of glucose in the peripheral tissue and converts the gluconeogenic 
pathway. It can also stimulate net renal glucose production. However inhibition of 
insulin secretion is the primary physiological defense against decrease blood glucose 
and occurs at a plasma glucose concentration of less than 80 mg/dl. The response 
of sympathetic nervous system against hypoglycemia is activated by both circulat-
ing catecholamines and direct innervation results in increased fat metabolism of 
lipolysis in adipocytes which release free fatty acid. It is estimated that 25% of the 
total defense against hypoglycemia by the contribution of free fatty acid. Cortisol 
and growth hormone are metabolic defense which are released in response to pro-
longed hypoglycemia; but they have modest significant effect on glucose counter-
regulation during acute stage. The actions of these hormones are increasing glucose 
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production and restraining glucose disposal after 4 h onset of hypoglycemia. It has 
only 20% of counter-regulatory response compared to the action of epinephrine.
If counter-regulatory mechanism fails to maintain the glucose homeostasis and 
blood glucose value of 3.0–3.5 mmol/l, may trigger the autonomic nervous system 
mediated warning symptoms such as sweating, palpitation and hunger to warn sub-
jective awareness of hypoglycemia and provoke feeling of eating to improve blood 
glucose level. If not consume adequate glucose during this stage, central nervous 
deprives for glucose, neuroglycopenia develops and cognitive function declines. 
Counter-regulatory responses to hypoglycemia also referred to as glycemic thresh-
olds and may be altered to higher plasma glucose levels following chronic hyper-
glycemia [26] or to lower plasma glucose levels following repeated hypoglycemia 
[27–29]. On the whole, the magnitude of counter-regulatory function is decrease 
with age 18 and is more obvious in male than in female [30].
6. Hypoglycemia and glycemic threshold
The glycemic threshold has a dynamic and significant role in the activation of 
counter-regulatory physiological response against the low plasma glucose level [20]. 
Though the individuals have increased level of glycated hemoglobin (HbA1C) may 
perceive the symptoms of hypoglycemia at higher blood individuals who undergo 
intensive glucose level with diabetes [31]. It means sudden and rapid declines of 
blood glucose from higher level to a lower but not too low and at this level brain 
started reacting to change and release of counter-regulatory hormones. This 
phenomenon is called “relative hypoglycemia” and it is self-limiting. Brain will 
usually takes 2–4 weeks to readjust and to improve that relatively reduced circulat-
ing glucose levels [27, 31–34].
In contrast, among diabetic patients who are on the intensive treatment of 
control of plasma glucose level may not perceive hypoglycemia until their plasma 
glucose is considerably lower than the normal physiological glycemic thresholds 
[33, 35]. The changes in this glycemic control are highly influenced chronically 
by persistent hyperglycemia and acutely by antecedent hypoglycemia [12, 35–38]. 
Antecedent hypoglycemia is a condition caused by hypoglycemia itself which 
impairs and reduces the reduced neuroendocrine and symptomatic responses 
to subsequent hypoglycemia. An experimental study found that there is a sig-
nificant reduction in glucagon, epinephrine, cortisol, pancreatic polypeptide 
responses to next-day of hypoglycemia among antecedent hypoglycemic patients 
who experienced two episodes with the blood glucose level of 50 mg/dl. It was 
also demonstrated that antecedent hypoglycemia reduced the neurogenic and 
neuroglycopenic symptom responses [28]. In later another study investigated the 
responses of metabolic and neuroendocrine on the effect of morning hypoglycemia 
to subsequent afternoon hypoglycemia. The findings revealed that only one pro-
longed, moderate hypoglycemic episode can also blunt the substantial changes of 
physiological counter-regulatory defense and the neurogenic and neuroglycopenic 
symptom response to subsequent hypoglycemia [39].
This impaired counter-regulatory responses otherwise called as “hypoglycemia-
associated autonomic failure” causes reduced neuroendocrine counter-regulatory 
responses to hypoglycemia and lowered glycemic thresholds for activation of physi-
ological defenses against hypoglycemia, which together lead to a condition called 
hypoglycemic unawareness. During this stage, because of failure to trigger the 
epinephrine secretion against severe drop in blood sugar, the individuals unaware of 
hypoglycemic symptoms of sweating, palpitation, anxiety generated by epinephrine. 
These symptoms are very significantly important to warn the individuals of the 
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lowering blood glucose level. Same scenario happened in intensively treated type 1 
and type 2 diabetic individuals due to shifting of glycemic threshold to lower plasma 
glucose level [33, 39–42] which further limits the efforts to attain euglycemia [37, 38].
7. Clinical manifestations of hypoglycemia
Hypoglycemic signs and symptoms (Table 3) may occur unexpectedly and 
suddenly depends on the blood glucose level and may also vary from one person to 
another. The hyperglycemic individuals who have blood glucose level with 200 mg/dl 
or greater may feel adrenergic hypoglycemic symptoms when blood glucose sud-
denly falls to 120 mg/dl or less. Whereas a person with usual blood glucose levels in 
the low range may not experience symptoms when blood glucose slowly drops under 
50 mg/dl and also patients who have had diabetes for many years have decreased 
hormonal (adrenergic) response to hypoglycemia.
Hypoglycemic symptoms may manifest as neurogenic (autonomic) symptoms 
and cholinergic-mediated symptoms. Low blood glucose level triggered the neu-
rogenic symptoms by activating the autonomic nervous system which releases 
the catecholamines (norepinephrine and epinephrine) from the adrenal medullae 
and acetylcholine from postsynaptic sympathetic nerve endings. Elevated epi-
nephrine levels leads the symptoms and signs of shakiness, palpitations, sweating, 
nervousness, anxiety, pupil dilation, dry mouth, pallor. The cholinergic-mediated 
symptoms are hunger, diaphoresis and paresthesia. However, only 20% of the total 
neurogenic symptom was found during hypoglycemia among epinephrine infusion 
in intensively and conventionally treated euglycemic type 1 diabetic individuals 
which indicates that the symptoms of hypoglycemic is multifocal and is mainly 
araised from efferent pathways of central nervous system [43].
Neuroglycopenic symptoms occur as a result of deprivation of glucose in the 
brain cells during hypoglycemia. Neuroglycopenic symptoms are very difficult 
to perceive by an individual rather it is most often recognized by family mem-
bers, friends and bystanders. These symptoms include irritability, confusion, 
aphasia, paresthesias, ataxia, headache and the most severe symptoms are 
seizures stupor, coma, and even death. It can also include transient focal neuro-
logical deficits such as diplopia, hemiparesis.
Autonomic symptoms Neuroglycopenic symptoms
Sweating
Tingling
Trembling
Feeling shaky
Feeling hungry
Palpitations
Anxiety
Blurred vision
Difficulty speaking
Feeling faint
Difficulty thinking
Confusion
Dizziness
Feeling drowsy
Irritability
Autonomic signs Neuroglycopenic signs
Tachycardia
Increased systolic blood pressure
Pallor
Diaphoresis
Mydriasis
Transient Focal Neurological Deficit occasionally
Table 3. 
Signs and symptoms of hypoglycemia.
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Neurogenic and neuroglycopenic symptoms are manifested by the activation of 
the sympatho-adrenal system and brain’s glucose deprivation. The brain is continu-
ously depends on a circulating glucose for energy and for cognitive function. If 
blood glucose levels fall causes cognitive dysfunction [44]. The 11 most commonly 
reported symptoms were used to form the Edinburgh Hypoglycemia Scale [45] and 
are reproduced in Table 4.
8. Levels of hypoglycemia
According to the blood glucose level and manifestation of signs and symptoms 
in response to low blood glucose level, hypoglycemia can be categorized into Level I, 
Level II and Level III or mild, moderate and severe hypoglycemia.
8.1 Level I (mild) hypoglycemia
The range of blood glucose level is 54–70 mg/dl. Symptoms include tremor, 
palpitations, tachycardia, nervousness, sweating and hunger due to sympathetic 
nervous system is stimulation.
8.2 Level II (moderate) hypoglycemia
The range of blood glucose level is 40–54 mg/dl. It may produce confusion, 
irritation, inability to concentrate, headache, lightheadedness, memory loss, 
numbness of the lips and tongue, slurred speech, lack of coordination, emotional 
changes, drowsiness, and double vision, or any combination of these symptoms due 
to impaired function of central nervous system.
8.3 Level III (severe hypoglycemia)
In severe hypoglycemia, the blood glucose level is less than 40 mg/dl. Central 
nervous system function is impaired further. Symptoms may include disoriented 
behavior, seizures, stupor, or loss of consciousness. During this stage they need help 
from another as they unable to function because of physical and mental changes.
9.  Mechanisms of counter-regulatory responses to hypoglycemia in type 
1 diabetes
Type 1 diabetes mellitus is otherwise called insulin dependent diabetes mellitus 
which occur due to little production of insulin or no insulin from pancreatic beta-
cells characterized by hyperglycemia and its associated symptoms. The treatment 
include for the management of diabetes mellitus is insulin, diet and exercise and 
Autonomic Neuroglycopenic General malaise
Sweating
Palpitations
Shaking
Hunger
Confusion
Drowsiness
Odd behavior
Speech difficulty
Incoordination
Headache
Nausea
Table 4. 
Edinburgh hypoglycemia scale.
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lifestyle modification. Insulin helps to convert the glucose into glycogen and store 
in the liver and muscles. If there is an imbalance between the insulin administration 
and food intake leads to hypoglycemia. Physiologically glucagon will be secreted 
by the pancreatic alpha-cells to convert the stored glycogen into glucose or from 
non-carbohydrate substances. However in patients with type 1 diabetes for more 
than years epinephrine is main physiological defense in response to hypoglycemia 
because glucagon secretory response to hypoglycemia is irreversibly lost. In later, 
epinephrine response to hypoglycemia also impaired unfortunately among patients 
with type 1 diabetes undergoing intensive treatment of insulin and at greater risk 
for recurrent hypoglycemia [46, 47]. There is more than 50% reduction in counter-
regulatory responses toward the future hypoglycemia due to repeated attack of 
hypoglycemia which results in vicious cycle of iatrogenic hypoglycemia-associated 
autonomic failure and also subsequent hypoglycemia may also leads to anteced-
ent hypoglycemia. Even short durations 20 minutes of antecedent hypoglycemia 
can produce significant impairment in counter-regulatory responses and also two 
episodes of hypoglycemia of 70 mg/dl can also blunt subsequent counter-regulatory 
responses by ∼30% in men [48]. Patient may experience severe and significant 
clinical consequences due to reduced adrenergic sensitivity of poor tissue respon-
sive to circulating epinephrine and deficient responses of glucagon with reduction 
in ANS counter-regulatory responses. These patients also had reduced β-adrenergic 
sensitivity compared to patients with normal counter-regulatory responses to 
hypoglycemia and healthy control subjects [49] and had reduced whole-body tissue 
sensitivity to epinephrine, which was exacerbated by intensive glycemic control. 
This reduced tissue responsiveness to epinephrine is an additional contributor to 
the syndrome of hypoglycemia-associated autonomic failure and reduced tissue 
sensitivity to epinephrine resulted in decrease endogenous glucose production and 
less inhibition of insulin-stimulated glucose uptake. Despite with persistent blunted 
epinephrine response to hypoglycemia, hypoglycemic symptom and β-adrenergic 
sensitivity responses increase [50] to restore the endocrine and autonomic function. 
Although controversial, other studies have also stated that with strict avoidance of 
antecedent hypoglycemia some or all of the features of hypoglycemia-associated 
autonomic failure can be reversed [51–53].
9.1  Mechanisms of counter-regulatory responses to hypoglycemia in type 2 
diabetes
Type 2 diabetes mellitus is a heterogeneous group of disease caused by inadequate 
secretion of insulin or improper utilization of secreted insulin or both. It may the 
affect all groups of people from children to older adults. Children are more com-
monly affected nowadays due to rise in childhood obesity. Treatment regime includes 
diet, exercise, oral hypoglycemic agents, glucagon like peptide-1 analogs, insulin, 
or combination of these and varies depending on the response to treatment and 
progressive β-cell failure [54]. The symptoms of hypoglycemia associated autonomic 
failure among type 2 diabetes depends on age, treatment modality (diet versus oral 
hypoglycemic agents versus insulin), comorbidity, body fat composition, metabolic 
control, and the presence of diabetic neuropathies [54, 55]. However, neuroendo-
crine contributes in glycemic responses to hypoglycemia in advanced type 2 diabetes. 
The glucagon response to low blood glucose level was also absent in advanced 
insulin-treated type 2 diabetes. Autonomic and symptomatic responses by glycemic 
threshold to hypoglycemia were also altered to lower plasma glucose concentrations 
by recent antecedent hypoglycemia. Hence, the risk for hypoglycemia-associated 
autonomic failure was high in advanced type 2 diabetes as like those with type 1 
diabetes and leads to harmful cycle of recurrent iatrogenic hypoglycemia [46, 55].
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10. Inborn errors of metabolism causing hypoglycemia
Non-diabetic hypoglycemia also results from inborn errors of metabolism. 
Such hypoglycemia most commonly occurs in infancy but can also occur in adult-
hood. Cases in adults can be classified into those resulting in fasting hypoglycemia, 
postprandial hypoglycemia, and exercise-induced hypoglycemia.
10.1 Fasting (postabsorptive) hypoglycemia
It is rare; disorders of glycogenolysis can result in fasting hypoglycemia. These 
disorders include glycogen storage disease (GSD) of types 0, 1, 3, and 4 and 
Fanconi-Bickel syndrome.
10.2 Patients with GSD
Type 1 and 3 characteristically have high blood lactate levels before and after 
meals, respectively. Both groups have hypertriglyceridemia, but ketones are high 
in GSD type 3. Defects in fatty acid oxidation also result in fasting hypoglyce-
mia. These defects can include (1) defects in the carnitine cycle; (2) fatty-acid 
β-oxidation disorders; (3) electron transfer disturbances; and (4) ketogenesis 
disorders. Finally, defects in gluconeogenesis (fructose-1, 6-biphosphatase) have 
been reported to result in recurrent hypoglycemia and lactic acidosis.
10.3 Postprandial (reactive) hypoglycemia
Inborn errors of metabolism resulting in postprandial hypoglycemia are also 
rare. These errors include (1) glucokinase, SUR1, and Kir6.2 potassium channel 
mutations; (2) congenital disorders of glycosylation; and (3) inherited fructose 
intolerance.
10.4 Exercise-induced hypoglycemia
Exercise-induced hypoglycemia, by definition, follows exercise. It results in 
hyperinsulinemia caused by increased activity of monocarboxylate transporter 1 in 
β cells.
11. Accidental, surreptitious, or malicious hypoglycemia
Hypoglycemia caused by endogenous hyperinsulinism due to functional β-cell 
disorders, insulinoma, or the insulin autoimmune syndrome is called as accidental, 
surreptitious, or malicious hypoglycemia. It may also occur by accidental admin-
istration of insulin, or accidental ingestion of an insulin secretagogue such as 
sulfonylurea because ingestion of an insulin secretagogue causes hypoglycemia with 
increased C-peptide levels and hypoglycemia caused by exogenous insulin with 
decrease C-peptide levels reflecting suppression of insulin secretion.
12. Assessment and diagnostic methods
• History collection
• Physical examination
Blood Glucose Levels
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• Diagnostic investigation: It includes
• Glucose—fasting and postprandial blood glucose
• Complete blood count
• Insulin
• C-peptide
• Beta-hydroxybutyrate
• Proinsulin
• Antibodies for insulin and its receptors
• Sulfonylurea and meglitinide screen
• Electrolytes, BUN/Cr, UA
• liver function tests,
• cortisol and thyroid levels, growth hormone level
• Other tests: CT and MRI
Whipple triad is the clinical presentation of pancreatic insulinoma and consists 
of: fasting hypoglycemia (<50 mg/dl), symptoms of hypoglycemia, immediate 
relief of symptoms after the administration of IV glucose.
13. Management of hypoglycemia
The aim of the treatment includes correction of glucose deficiency, prevent the 
complication associated with hypoglycemia and treat the underlying the cause. 
Treat the patient in the emergency department as shown in the Figure 1.
• History collection and physical examination
• Check the blood glucose—capillary blood glucose
• Assess the mental status of the client
• Access intravenous line if needed
• Monitor blood glucose level
• Administer 15 g of fast acting glucose in the form of glucose tablets or glucose 
containing fluids, candy or food. For, e.g., three or four commercially prepared 
glucose tablets; 4–6 oz. of fruit juice or regular soda, 6–10 hard candies, 2–3 
tsp. of sugar or honey is appropriate if the patient is able to take orally
• Check for blood glucose 15 min later.
13
Hypoglycemia: Essential Clinical Guidelines
DOI: http://dx.doi.org/10.5772/intechopen.86994
• Instruct the patient to eat protein and carbohydrate containing snack to 
maintain their blood glucose after 60 min if the blood glucose is higher than 
70 mg/dl
• Treatment is repeated with 15 g of carbohydrates if glucose level is remains 
less than 70 mg/dl after the initial intake of 15 g of glucose. It may be probably 
repeated up to 1–3 times
• Instruct the patient to avoid adding more table sugar to juice, even “unsweet-
ened” juice, which may cause a sudden increase in glucose, resulting in hyper-
glycemia in later hours.
• Administer parenteral therapy with 25% dextrose if unable to take oral foods
• Administer inj. glucagon 1.0 mg subcutaneous/intramuscular can be used 
especially in type 1 diabetes mellitus.
• The somatostatin analog octreotide can be used to suppress insulin secretion in 
sulfonylurea-induced hypoglycemia.
• Identify and treat the underlying cause
13.1 Management of hypoglycemia in the unconscious patient
• Assessment of glasgow coma scale
• Monitor airway, breathing, circulation
• Constant monitoring of blood glucose level
• Administer 1 g of glucagon subcutaneously or intravenously
• Administer 50% dextrose in 25–50 mL of water intravenously
Figure 1. 
Schematic representation of emergency management of hypoglycemia.
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• Check the patient for regaining from the state of unconsciousness. If hypogly-
cemic state extends for more than 5 h results in profound hypoglycemia which 
may cause permanent brain damage.
• Administer IV Mannitol and dexamethasone, IV glucose with constant glucose 
monitoring to necessary until regain from the state of unconsciousness to 
conscious and restore normal brain function
13.2 Management of non-diabetic hypoglycemia
Depend on the underlying etiology
• Discontinue the offending drugs or reduce their doses
• Treat the underlying critical illnesses
• Replace the cortisol and growth hormone if levels are deficient.
• Surgical, radiotherapeutic, or chemotherapeutic reduction of a non–islet cell 
tumor.
• Surgical resection of an insulinoma is curative
• Medical therapy with diazoxide or octreotide can be used if resection is not 
possible and in patient with a non-tumor beta cell tumor
13.3 Health education
• Consult with a dietitian to develop or adjust meal plan to maintain consistency 
in carbohydrates at meals by calculating grams of carbohydrates so that plan 
for medication and/or insulin.
• Self-monitoring of blood glucose to detect the episodes of hypoglycemia at 
the earliest. Self-monitoring of blood glucose level should give an idea of what 
makes the blood glucose level drop.
• Do not skip meal and balance the meal plan with insulin or oral hypoglycemic 
agent.
• Quit alcohol and smoking.
• Maintain the body weight.
• Follow medication dose regularly.
• Avoidance of exercise while having the symptoms of hypoglycemia.
• Ingestion of carbohydrate especially rapidly absorbed glucose during the 
symptoms of hypoglycemia.
• Remember and follow rule of 15 which means 15 g of glucose raise 50 mg/dl in 
15 min during hypoglycemia state.
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• Intravenous glucose is the preferable treatment of severe hypoglycemia, par-
ticularly that caused by a sulfonylurea.
• Keeping the hypo box hypoglycemic kit which contains glucose, glucagon, juice, 
etc.
• Instructing the family members and care givers about usage this kit, check for 
expiry date and replacing the used content in the kit.
• Always carry the sweetener which contains easily absorbable simple sugar and 
identity card.
• Regular check-up and follow-up care.
14. Conclusion
Hypoglycemia is a common, potentially avoidable consequence of diabetes 
treatment. This chapter emphasis on causes and risk factors of hypoglycemia, 
recognition of symptoms of hypoglycemia, glucose regulatory and counter regula-
tory mechanism, management and prevention of hypoglycemia thereby prevent the 
potential complications of hypoglycemia. Health care professionals have a major 
role in educating clients with diabetes mellitus about hypoglycemia and to follow 
their hypoglycemia management plan while caring the clients.
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